Safety Follow-up Study of Participants Previously Dosed With INV-347 in the First-in-Human Study INV-CL-108
Latest Information Update: 12 Sep 2025
At a glance
- Drugs INV 347 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
Most Recent Events
- 12 Sep 2025 New trial record